Pancreatic Cancer Research

ResearcherUniversity of DelawareActive in the last 2 years

Charles J. Yeo

ORCID-verified (high confidence, 0.95), identity_conf@1As of 6 November 2026

Matched on ORCID iD 0000-0001-8097-0071; OpenAlex author ID A5025415933. Sources: OpenAlex.

Their work

Papers
84 (first author 3, last author 9)
Trials
0
Grants
0
Labs led
1
Collaborators
185
Papers, trials and grants by year

2011: 8 papers · 2012: 4 papers · 2013: 6 papers · 2014: 8 papers · 2015: 6 papers · 2016: 8 papers · 2017: 3 papers · 2018: 8 papers · 2019: 3 papers · 2020: 5 papers · 2021: 6 papers · 2022: 4 papers · 2023: 3 papers · 2024: 3 papers · 2025: 5 papers · 2026: 4 papers

Papers 50 of 84

  1. Initial Site of Metastasis Influences Prognosis in Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1002/cam4.71760↗
  2. Preoperative Glucose-to-Albumin Ratio as a Prognostic Marker for Survival in Pancreatic Cancer Patients Undergoing Pancreatectomy. Co-author DOI 10.1002/cam4.72256↗
  3. Pancreatic Cancer-Advances in the Last 50 Years. Last author DOI 10.1002/wjs.70309↗
  4. Survival Impact of Intraoperative Carbon Dioxide Dysregulation in Patients Undergoing Pancreaticoduodenectomy for Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1097/xcs.0000000000001760↗
  5. Clinical Implications of Mismatch Repair Deficiency in Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1002/cam4.70960↗
  6. P53 Function Status Correlates With Overall Survival in Patients With Resected Pancreatic Cancer. Co-author DOI 10.1002/jso.70060↗
  7. Targeting BARD1 suppresses a Myc-dependent transcriptional program and tumor growth in pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.neo.2025.101152↗
  8. Prognostic Properties of KRAS Gene Mutation Subtypes in Resected Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1097/mpa.0000000000002458↗
  9. Gene Expression Profiling of Pancreatic Ductal Adenocarcinoma Cells in Hypercapnia Identifies SIAH3 as a Novel Prognostic Biomarker. Co-author DOI 10.3390/ijms26072848↗
  10. Early outcomes of MR-guided SBRT for patients with recurrent pancreatic adenocarcinoma. Co-author DOI 10.1186/s13014-024-02457-y↗
  11. The Clinical Implications of KRAS Mutations and Variant Allele Frequencies in Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.3390/jcm13072103↗
  12. Association of Mutant KRAS Alleles With Morphology and Clinical Outcomes in Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.5858/arpa.2023-0005-oa↗
  13. Hypercapnic Tissue Gene Expression and Survival in Early-Stage Pancreatic Ductal Adenocarcinoma. Last author DOI 10.1097/xcs.0000000000000552↗
  14. Repurposing the FDA-approved anthelmintic pyrvinium pamoate for pancreatic cancer treatment: study protocol for a phase I clinical trial in early-stage pancrea… Co-author DOI 10.1136/bmjopen-2023-073839↗
  15. Association of Pancreatic Adenocarcinoma Location With DNA Damage Response Status and Response to Platinum-Based Therapy. Co-author DOI 10.1200/po.22.00648↗
  16. KRAS mutation allele frequency threshold alters prognosis in right-sided resected pancreatic cancer. Co-author DOI 10.1002/jso.26860↗
  17. A Phase 3 Randomized Clinical Trial of Chemotherapy With or Without Algenpantucel-L (HyperAcute-Pancreas) Immunotherapy in Subjects With Borderline Resectable … Co-author DOI 10.1097/sla.0000000000004669↗
  18. The RNA-Binding Protein HuR Posttranscriptionally Regulates the Protumorigenic Activator YAP1 in Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1128/mcb.00018-22↗
  19. HuR Plays a Role in Double-Strand Break Repair in Pancreatic Cancer Cells and Regulates Functional BRCA1-Associated-Ring-Domain-1(BARD1) Isoforms. Co-author DOI 10.3390/cancers14071848↗
  20. Multi-agent neoadjuvant chemotherapy improves survival in early-stage pancreatic cancer: A National Cancer Database analysis. Co-author DOI 10.1016/j.ejca.2021.01.004↗
  21. Pancreatic Cancer-Associated Diabetes is Clinically Distinguishable From Conventional Diabetes. Co-author DOI 10.1016/j.jss.2020.12.015↗
  22. Isolated Ovarian Metastasis from Pancreatic Cancer Mimicking Primary Ovarian Neoplasia: Role of Molecular Analysis in Determining Diagnosis. Co-author DOI 10.1089/pancan.2021.0001↗
  23. The FDA-Approved Anthelmintic Pyrvinium Pamoate Inhibits Pancreatic Cancer Cells in Nutrient-Depleted Conditions by Targeting the Mitochondria. Co-author DOI 10.1158/1535-7163.mct-20-0652↗
  24. AraC-FdUMP[10] Is a Next-Generation Fluoropyrimidine with Potent Antitumor Activity in PDAC and Synergy with PARG Inhibition. Co-author DOI 10.1158/1541-7786.mcr-20-0985↗
  25. Margin-Positive Pancreatic Ductal Adenocarcinoma during Pancreaticoduodenectomy: Additional Resection Does Not Improve Survival. Co-author DOI 10.1245/s10434-020-09000-9↗
  26. Optimizing cancer cure dialog: an analysis of pancreatic cancer patients' views regarding survival and cure. Co-author DOI 10.1007/s00520-019-05214-0↗
  27. Surgical Outcomes After Pancreatic Resection of Screening-Detected Lesions in Individuals at High Risk for Developing Pancreatic Cancer. Co-author DOI 10.1007/s11605-019-04230-z↗
  28. Effect of Hypercapnia, an Element of Obstructive Respiratory Disorder, on Pancreatic Cancer Chemoresistance and Progression. Co-author DOI 10.1016/j.jamcollsurg.2019.12.033↗
  29. Advanced Endoscopic Rescue of a Complication (Duodenojejunostomy Leak) After a Pylorus-Preserving Pancreaticoduodenectomy in a Post-Esophagectomy Patient with … Last author DOI 10.1089/pancan.2019.0016↗
  30. ASO Author Reflections: Margin-Positive Pancreatic Ductal Adenocarcinoma During Pancreaticoduodenectomy: Additional Resection Does Not Improve Survival. Co-author DOI 10.1245/s10434-020-09031-2↗
  31. Call for Papers: Journal of Pancreatic Cancer. Co-author DOI 10.1089/pancan.2019.29013.cfp↗
  32. Poly (ADP) Ribose Glycohydrolase Can Be Effectively Targeted in Pancreatic Cancer. Co-author DOI 10.1158/0008-5472.can-18-3645↗
  33. Abemaciclib Is Effective Against Pancreatic Cancer Cells and Synergizes with HuR and YAP1 Inhibition. Co-author DOI 10.1158/1541-7786.mcr-19-0589↗
  34. Common Hepatic Artery Abutment or Encasement Is an Adverse Prognostic Factor in Patients with Borderline and Unresectable Pancreatic Cancer. Co-author DOI 10.1007/s11605-017-3595-7↗
  35. A Sub-Type of Familial Pancreatic Cancer: Evidence and Implications of Loss-of-Function Polymorphisms in Indoleamine-2,3-Dioxygenase-2. Co-author DOI 10.1016/j.jamcollsurg.2017.12.052↗
  36. Risk of Neoplastic Progression in Individuals at High Risk for Pancreatic Cancer Undergoing Long-term Surveillance. Co-author DOI 10.1053/j.gastro.2018.05.035↗
  37. Identification of a novel metabolic-related mutation (IDH1) in metastatic pancreatic cancer. Co-author DOI 10.1080/15384047.2016.1210743↗
  38. Genetic Drivers of Pancreatic Cancer Are Identical Between the Primary Tumor and a Secondary Lesion in a Long-Term (>5 Years) Survivor After a Whipple Procedur… Last author DOI 10.1089/pancan.2018.0015↗
  39. Cytoplasmic HuR Status Predicts Disease-free Survival in Resected Pancreatic Cancer: A Post-hoc Analysis From the International Phase III ESPAC-3 Clinical Tria… Co-author DOI 10.1097/sla.0000000000002088↗
  40. Symptom Clusters in Patients With Pancreatic Cancer Undergoing Surgical Resection: Part I. Last author DOI 10.1188/18.onf.e36-e52↗
  41. Clinical Implications of Extensive Lymph Node Metastases for Resected Pancreatic Cancer. Co-author DOI 10.1245/s10434-018-6763-4↗
  42. Microscopic lymphovascular invasion is an independent predictor of survival in resected pancreatic ductal adenocarcinoma. Co-author DOI 10.1002/jso.24723↗
  43. Perioperative Management of Factor V Leiden and Pancreatic Adenocarcinoma. Last author DOI 10.1089/pancan.2017.0010↗
  44. Posttranscriptional Upregulation of IDH1 by HuR Establishes a Powerful Survival Phenotype in Pancreatic Cancer Cells. Co-author DOI 10.1158/0008-5472.can-17-0015↗
  45. Modified Appleby Procedure with Arterial Reconstruction for Locally Advanced Pancreatic Adenocarcinoma: A Literature Review and Report of Three Unusual Cases. Last author DOI 10.1007/s11605-015-3001-2↗
  46. The mRNA-binding protein HuR promotes hypoxia-induced chemoresistance through posttranscriptional regulation of the proto-oncogene PIM1 in pancreatic cancer ce… Co-author DOI 10.1038/onc.2015.325↗
  47. WEE1 inhibition in pancreatic cancer cells is dependent on DNA repair status in a context dependent manner. Co-author DOI 10.1038/srep33323↗
  48. Medical Case Reporting for Pancreatic Cancer. Co-author DOI 10.1089/crpc.2015.29007.cjy↗
  49. "The Immune Conundrum": Acquired Hemophilia A, Immune Thrombocytopenia, and Neutropenia in a Patient with Pancreatic Cancer. Co-author DOI 10.1089/crpc.2015.29011.prg↗
  50. Thymoquinone Promotes Pancreatic Cancer Cell Death and Reduction of Tumor Size through Combined Inhibition of Histone Deacetylation and Induction of Histone Ac… Co-author DOI 10.1155/2016/1407840↗

Closest collaborators

The 25 strongest of 185 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Harish Lavu · 30 shared papers, 2011–2026 · strength 4.74
  2. Avinoam Nevler · 21 shared papers, 2017–2026 · strength 3.93
  3. Aditi Jain · 12 shared papers, 2019–2025 · strength 2.15
  4. Jonathan Robert Brody · 30 shared papers, 2011–2025 · strength 2.15
  5. Wei Jiang · 12 shared papers, 2016–2025 · strength 1.61
  6. Jordan Michael Winter · 22 shared papers, 2012–2021 · strength 1.45
  7. Richard Zheng · 5 shared papers, 2020–2026 · strength 1.14
  8. Christopher William Schultz · 8 shared papers, 2019–2023 · strength 0.88
  9. Michael Jon Pishvaian · 8 shared papers, 2016–2025 · strength 0.83
  10. Matthew McCoy · 4 shared papers, 2021–2025 · strength 0.60
  11. James A. Posey · 4 shared papers, 2019–2024 · strength 0.58
  12. Theresa Pluth Yeo · 5 shared papers, 2018–2023 · strength 0.57
  13. Andrea Feci · 2 shared papers, 2026 · strength 0.57
  14. Samantha Z. Brown · 5 shared papers, 2019–2022 · strength 0.56
  15. Rosalie C. Sears · 3 shared papers, 2022–2025 · strength 0.51
  16. David O. Nauheim · 4 shared papers, 2020–2022 · strength 0.50
  17. Atrayee Basu Mallick · 3 shared papers, 2021–2024 · strength 0.49
  18. Faria Nusrat · 2 shared papers, 2024–2025 · strength 0.47
  19. Agnieszka Katarzyna Witkiewicz · 11 shared papers, 2011–2016 · strength 0.41
  20. Hwyda A. Arafat · 10 shared papers, 2011–2016 · strength 0.41
  21. Grace A. McCarthy · 4 shared papers, 2019–2022 · strength 0.39
  22. Talia Golan · 4 shared papers, 2019–2021 · strength 0.37
  23. Eleanor Mancheski · 1 shared paper, 2026 · strength 0.36
  24. Savio George Barreto · 1 shared paper, 2026 · strength 0.36
  25. Eileen Mary O'Reilly · 1 shared paper, 2026 · strength 0.36

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.